These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 23117668)

  • 1. [Laboratory diagnostic with regard to new anticoagulants - monitoring and influence on coagulation tests].
    Nagler M; Wuillemin W
    Ther Umsch; 2012 Nov; 69(11):650-6. PubMed ID: 23117668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [New oral anticoagulants in venous thromboembolism. General practice information on switching, monitoring, pausing].
    Oberhofer E
    MMW Fortschr Med; 2015 Jan; 157(1):24. PubMed ID: 25743289
    [No Abstract]   [Full Text] [Related]  

  • 3. Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban.
    Fawole A; Daw HA; Crowther MA
    Cleve Clin J Med; 2013 Jul; 80(7):443-51. PubMed ID: 23821689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The new Anticoagulants - Relevant Facts for the GP].
    Asmis LM
    Praxis (Bern 1994); 2011 Aug; 100(16):971-6. PubMed ID: 21833915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [General characteristics of the new oral anticoagulants].
    Gegu M; Chevalet P; Piloquet FX; Berrut G; De Decker L
    Geriatr Psychol Neuropsychiatr Vieil; 2013 Dec; 11(1 Suppl):4-9. PubMed ID: 24463058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/bleeding management. Australasian Society of Thrombosis and Haemostasis.
    Tran H; Joseph J; Young L; McRae S; Curnow J; Nandurkar H; Wood P; McLintock C
    Intern Med J; 2014 Jun; 44(6):525-36. PubMed ID: 24946813
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Management of direct action oral anticoagulants in the peri-operative period and invasive techniques].
    Llau JV; Ferrandis R; Castillo J; de Andrés J; Gomar C; Gómez-Luque A; Hidalgo F; Torres LM;
    Rev Esp Anestesiol Reanim; 2012; 59(6):321-30. PubMed ID: 22633209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new era of oral anticoagulation in atrial fibrillation: implications in clinical practice.
    Kasmeridis C; Lip GY; Apostolakis S
    Hosp Pract (1995); 2013 Feb; 41(1):61-70. PubMed ID: 23466968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [New oral anticoagulant agents: the quandary of anticoagulation in the elderly].
    Páramo JA
    Med Clin (Barc); 2013 Oct; 141(8):346-8. PubMed ID: 23831406
    [No Abstract]   [Full Text] [Related]  

  • 10. The laboratory and the new oral anticoagulants.
    Tripodi A
    Clin Chem; 2013 Feb; 59(2):353-62. PubMed ID: 23043068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approach to the new oral anticoagulants in family practice: part 1: comparing the options.
    Douketis J; Bell AD; Eikelboom J; Liew A
    Can Fam Physician; 2014 Nov; 60(11):989-95. PubMed ID: 25392438
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disadvantages of VKA and requirements for novel anticoagulants.
    Shameem R; Ansell J
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):103-14. PubMed ID: 23953899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
    Quinlan DJ; Eriksson BI
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oral anticoagulants for VTE prevention in orthopedic surgery: overview of phase 3 trials.
    Friedman RJ
    Orthopedics; 2011 Oct; 34(10):795-804. PubMed ID: 21956181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New oral anticoagulants are as safe in elderly patients as conventional drugs].
    Steurer J
    Praxis (Bern 1994); 2014 Aug; 103(17):1032. PubMed ID: 25146949
    [No Abstract]   [Full Text] [Related]  

  • 17. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY; Kim RB
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical pharmacological aspects of new oral anticoagulants].
    Haschke M
    Ther Umsch; 2012 Nov; 69(11):657-60. PubMed ID: 23117669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacology and safety of new oral anticoagulants: the challenge of bleeding persists.
    Levy JH
    Clin Lab Med; 2014 Sep; 34(3):443-52. PubMed ID: 25168936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
    Fenger-Eriksen C; Münster AM; Grove EL
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):651-9. PubMed ID: 24716468
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.